Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc (GSK) covers the period ending February 2015. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMRs), and connected persons under the UK Disclosure and Transparency Rules (DTR 3.1.4R).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price at the time of the transaction: 1,505.46 pence per Ordinary Share.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details share acquisitions made on February 10, 2015, through GSK's Share Reward Plan.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, management commentary, risk factors, contingencies, or unusual items. It is a regulatory disclosure of insider trading activity.
Important Facts for Investors
- Transaction Date: Shares were acquired on February 10, 2015.
- Share Price: 1,505.46 pence per Ordinary Share.
- Participants: Nine Directors/PDMRs and one connected person participated in the Share Reward Plan.
- Acquisition Structure: Participants acquired shares through both personal contribution and matching elements (GSK contribution).
- Volume: Most participants acquired 8 shares under each element; Dr. P J T Vallance acquired 9 shares under each element; Mrs. K Thomson (connected person) acquired 4 shares under each element.